ABT-263 Treatment also reduced the survival of TR9 Ron cells in absence of HGFL, suggesting that Bcl2 is an important survival factor in prostate cancer cells that prevents anoikis even in the absence of Ron activation. The gene discussed is BCL2; the disease is prostate carcinoma.